1 Purified preparation of FSH was also generated as a drug for WHO group II patients who did not need additional LH activity because their serum levels of LH remained adequate for the follicular development. Since human menopausal gonadotropin (hMG), which contains follicle stimulating hormone (FSH) and luteinizing hormone (LH), was established as a medical drug, it has been used broadly and successfully for patients with World Health Organization (WHO) group I and II ovulatory disorders.
Abnormal secretion of gonadotropin results in an ovulatory disorder that is a common cause of infertility in women. Gonadotropin is a hormone that controls ovarian function in women.
However, this protocol seemed uneffective for patients with unexplained infertility. Optimized protocol of low dose FSH therapy setting a starting dose 50 IU/62.5 IU by BMI with an increment dose of 12.5 IU was safe and highly effective in WHO group II anovulatory patients. No pregnancy was achieved in the OSpatients. Monofollicular development was 85.7% (BMI < 20) and 76.6% (BMI ≥ 20). In the OSpatients, the ovulation rate was 100%. In the OIpatients, the ovulation rate was 100% (BMI < 20 group) and 90.9% (BMI ≥ 20 group).
Study outcomes were ovulation, monofollicular development and other variables. The protocol of low dose step-up FSH therapy was optimized for the starting dose as 50 IU (body mass index < 20 group) and 62.5 IU (BMI ≥ 20 group) with the increment dose of 12.5 IU. MethodsĪnovulatory women with WHO group II ovulatory disorder (ovulation induction patients, n = 29), and with an unexplained infertility (ovarian stimulation patients, n = 21) were enrolled. To evaluate the optimized protocol of low dose follicle-stimulating hormone (FSH) therapy that has a starting dose of 50 IU/62.5 IU with a small increment dose (12.5 IU) for women with World Health Organization (WHO) II ovulatory disorder and unexplained infertility.